Schmidt David sold (to issuer) $772K of ASTH

Schmidt David sold (to issuer) 20,000 shares of Astrana Health, Inc. (ASTH) at $38.59 ($0.77M total) on 2026-08-14.

Original reporting
SEC EDGAR · Schmidt David
Published Aug 18, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 8:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ASTH
Neutral
medium confidence
Mentioned
$ASTH
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ASTHNeutralLow
01

Why it matters

The newest disclosed fact is the director’s sale of 20,000 shares at $38.59, totaling $771,800, with post-transaction holdings of 36,019 shares.

02

Market read

Traders may note insider selling activity, but there is no accompanying fundamental catalyst in the filing text.

03

What to watch

No 10b5-1 plan is cited, but the article also provides no reason for the sale, so interpreting it as a strong signal is risky.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-18 after-hours; transaction dated 2026-08-14

Background

The article is an SEC Form 4 insider transaction disclosure for Astrana Health, Inc.

Company-level read

Ticker impact

$ASTHNeutralMedium confidence
Context

Astrana Health director David Schmidt sold 20,000 shares to the issuer at $38.59 on 2026-08-14, per Form 4.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven unless follow-on filings show broader selling.

Evidence & confidence

The filing is a Form 4 insider transaction with a defined price and size, but it does not include new company fundamentals, guidance, or regulatory/legal developments.

Market effects

No sector-level signal; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Because the code indicates sale to the issuer, it may reflect routine buyback participation rather than a bearish view on the stock.

Key entities

  • Astrana Health, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Schmidt David

    Director who sold shares to the issuer.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ASTHHighAI 8/10

Astrana Health Earnings Call Highlights Growth and Deleveraging

Astrana Health (ASTH) reported Q3 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). The company highlighted organic growth, debt reduction, and favorable Medicare trends. Management maintained full-year guidance, expecting revenue of $3.9B-$4B and adjusted EBITDA of $261M-$274M. Challenges include Medicaid pressure and seasonality.

$ASTHMed

Astrana Health 3Q 2026: Revenue $1.02B, EPS $0.26 — 10-Q Summary

Astrana Health reported 3Q 2026 revenue of $1.02B, up 7% YoY, and net income of $13.0M, compared to $373K last year. Growth was driven by 9% increase in capitation revenue. Care Partners saw 8% revenue growth and 94% operating income rise, while Care Delivery revenue increased 5% but operating loss widened. Care Enablement revenue rose 5% with 4% higher operating income. Astrana managed 29 IPAs and 1.5M patients as of September 30, 2026.

$ASTHMed

Astrana Health Inc (ASTH) (Q3 2026) Earnings Call Highlights: Record Revenue and EBITDA

Astrana Health Inc (ASTH) reported Q3 2026 earnings, highlighting record revenue and EBITDA growth. CEO Brandon Sim discussed Medicaid membership attrition, Medicare Advantage dynamics, and care enablement business momentum. The company expects mid-teens EBITDA growth despite Medicaid headwinds. A cybersecurity incident is under investigation, and a new 'premiums at risk' disclosure was introduced for ACO business transparency.

$ASTHHighAI 8/10

Astrana Health (ASTH) Q3 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q3 2026 revenue of $1.02B (+7% YoY) and adjusted EBITDA of $77.2M (+13% YoY). Membership grew to 1.5M, with Medicare Advantage increasing organically. The company completed acquisitions and partnerships, expanding its presence. Medical cost trends were slightly better than expected, with Texas operations performing ahead of plan. Free cash flow reached $105M, and net leverage was reduced to 2.2x.

$ASTHMed

Astrana Health Q3 Earnings Call Highlights

Astrana Health reported 1.5 million members under management, with Medicare Advantage growth offsetting Medicaid attrition. The company expects Medicaid membership to decline 10-15% in 2027, impacting adjusted EBITDA. Medical cost trends were slightly better than expected, with Medicare Advantage margins stable. Astrana plans 82% of capitation revenue from full-risk arrangements by 2026 and completed acquisitions and partnerships.